jain.com

Standby Equity Purchase Agreement with Yorkville Advisors

Company: TeraWulf

This claim was marked delayed on September 15, 2026. Recorded automatically from the cited source when it was published, then queued for evidence review.

How this was decided: Automated extraction from the cited source. The claim is preserved below exactly as it was originally published, so the record shows what was asserted as well as what became of it.

Subject kind
financing
Statement date
2022-06-12
Promised by
2025-06-02
Promised amount
50000000.0 USD
Current status
delayed

The claim, verbatim

TeraWulf will be able to sell shares of Common Stock having an aggregate gross sales price of up to $50,000,000 at the Company's request any time during the 36 months following June 2, 2022

Source (primary)

TeraWulf 424B5 filed 2022-06-13 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗

Quote: “TeraWulf Inc. (the "Company") will be able to sell shares of Common Stock having an aggregate gross sales price of up to $50,000,000 at the Company's request any time during the 36 months following the date of the SEPA.”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms TeraWulf 424B5 filed 2022-06-13

Quote: “TeraWulf Inc. (the "Company") will be able to sell shares of Common Stock having an aggregate gross sales price of up to $50,000,000 at the Company's request any time during the 36 months following the date of the SEPA.”

View cached copy (2026-09-13)Live source ↗

Record of changes

September 14, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 15, 2026 — delayed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.